Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 2/20 | 0.53 |
| ▸ | PARP1 | P09874 | 3/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 5/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CD38 | P28907 | 1/20 | 0.39 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.39 |
| ▸ | CBLB | Q13191 | 1/20 | 0.39 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4123848 | 0.85 | CTSS (0.54) | CTSSMAOBLMNAGAATAS2R14 | |
| SCHEMBL27908376 | 0.85 | MAPK10 (0.40) | CTSSPARP1MAPK10MAPK8LMNA | |
| SCHEMBL4119115 | 0.83 | CTSS (0.56) | CTSSMAOBLMNAGAATAS2R14 | |
| SCHEMBL17339302 | 0.83 | CTSS (0.53) | CTSSMAOBLMNAGAACTSK | |
| SCHEMBL3395132 | 0.82 | PARP1 (0.47) | PARP1MAPK10GAA | |
| SCHEMBL6024762 | 0.81 | CTSS (0.61) | CTSSMAOBMAPK10LMNAGAA | |
| SCHEMBL28130468 | 0.78 | CYP3A4 (0.55) | CTSSMAPK10MAPK8LMNACYP3A4 | |
| SCHEMBL16829403 | 0.78 | CTSS (0.44) | CTSSMAOBGAACYP3A4 | |
| SCHEMBL528652 | 0.77 | LMNA (0.43) | PARP1LMNA | |
| SCHEMBL29629424 | 0.77 | TAS2R14 (0.53) | CTSSPARP1LMNAGAACTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1836174-A2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC. (US) | 2007-09-26 | — | — | EP | claimed |
| WO-2006039718-A2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2006-04-13 | — | — | WO | claimed |
| US-20090118276-A1 | THIENOPYRIMIDINES, THIENOPYRIDINES, AND PYRROLOPYRIMIDINES AS B-RAF INHIBITORS | WYETH (US) | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118276-A1 | THIENOPYRIMIDINES, THIENOPYRIDINES, AND PYRROLOPYRIMIDINES AS B-RAF INHIBITORS | BRAF, ARAF, RAF1 | CTSS 4665/4885PARP1 1174/4885MAOB 963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.